HIHisae Iinuma

Hisae Iinuma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hisae Iinuma has a total of 146 co-authors. Here are the top co-authors by number of shared publications:

  • Ryoji Fukushima

    Department of Surgery, Teikyo University School of Medicine, Itabashi, Tokyo 173‑0003, Japan

    6 shared publications
  • Atsushi Horiuchi

    5 shared publications
  • Junko Tamura

    5 shared publications
  • Kota Okinaga

    From Teikyo University School of Medicine; and Gastroenterology Center, International University of Health and Welfare Mita Hospital, Tokyo; Medical Institute of Bioregulation, Kyushu University, Oita; Graduate School of Medical Sciences, Kumamoto University, Kumamoto; Hyogo College of Medicine, Hyogo; Graduate School of Medicine, Osaka University, Osaka, Japan

    4 shared publications
  • Ryu Shimada

    Department of Surgery, Teikyo University School of Medicine, Tokyo 173‑0003, Japan

    4 shared publications
  • Takuya Akahane

    Department of Surgery, Teikyo University School of Medicine, Tokyo 173‑0003, Japan

    4 shared publications

Latest Publications

  • Open Access

    Plasma exosome‑encapsulated microRNA‑21 and microRNA‑92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer

    by Naruyoshi Soeda, Hisae Iinuma, Yusuke Suzuki, Daisuke Tsukahara, Hironori Midorikawa, Yuichi Igarashi, Yoshimasa Kumata, Masahiro Horikawa, Takashi Kiyokawa, Takeo Fukagawa, et al.

    In patients with gastric cancer (GC), peritoneal recurrence is a common risk and associated with poor prognosis. A novel biomarker for the prediction of high‑risk peritoneal recurrence in patients with GC is desirable. The present study investigated the effectiveness of exosome‑encapsulated microRNAs (ex‑miRNAs) as minimally invasive biomarkers in patients with GC that received curative surgery. Recurrence‑specific ex‑miRNAs were selected following comparison of miRNA microarray data from patients with TNM stage II GC with peritoneal recurrence (n=3) and without peritoneal recurrence following curative surgery (n=3), and three healthy volunteers. In this analysis, exosome‑encapsulated miRNA‑21 (ex‑miR‑21) and exosomal miR‑92a (ex‑miR‑92a) exhibited the greatest alterations in expression patterns. Using plasma exosome samples collected from another 129 patients with stage II and III GC, the present study investigated the potential value of ex‑miR‑21 and ex‑miR‑92a as biomarkers. Ex‑miRNA levels were measured using TaqMan miRNA assays. Ex‑miR‑21 levels were significantly higher and ex‑miR‑92a levels were significantly lower in samples from patients with GC compared with healthy controls. The overall survival (OS) and peritoneal recurrence‑free survival (PRFS) were poorer in stage II and III patients with high ex‑miR‑21 levels than in patients with low miR‑21 levels. OS and PRFS of stage II and III patients with low ex‑miR92a levels were significantly worse than those with high ex‑miR92a levels. Cox multivariate analyses indicated that ex‑miR‑21 and ex‑miR‑92a were independent prognostic factors for OS and PRFS in stage II and III GC. A negative correlation was detected between expression levels of miR‑21 and programmed cell death protein 4 mRNA, and miR‑92a and prostaglandin E receptor 4 mRNA. Therefore, ex‑miR‑21 and ex‑miR‑92a may function as effective and minimally invasive biomarkers for the prediction of peritoneal recurrence and the prognosis of patients with stage II/III GC.


  • Plasma exosomal microRNA‑125b as a monitoring biomarker of resistance to mFOLFOX6‑based chemotherapy in advanced and recurrent colorectal cancer patients

    by Takahiro Yagi, Hisae Iinuma, Tamuro Hayama, Keiji Matsuda, Keijirou Nozawa, Mitsuo Tsukamoto, Ryu Shimada, Takuya Akahane, Takeshi Tsuchiya, Tsuyoshi Ozawa, et al.

    Liquid biomarkers for the early detection of resistance to chemotherapy are important for improving prognosis. This study investigated the usefulness of plasma exosomal microRNA‑125b (ex‑miRNA‑125b) for the early detection of resistance to modified fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)‑based first‑line chemotherapy in patients with advanced or recurrent (advanced/recurrent) colorectal cancer (CRC). First, ex‑miRNAs associated with resistance to mFOLFOX6‑based chemotherapy were profiled via miRNA microarray analysis. In this analysis, ex‑miR‑125b exhibited the greatest upregulation in patients with progressive disease (PD) compared with the findings for patients with stable disease (SD) and healthy controls. Next, another 55 patients with advanced/recurrent CRC who received mFOLFOX6‑based first‑line chemotherapy underwent a validation study of ex‑miR‑125b. Blood samples were collected before and during treatment until tumor progression. Ex‑miRNA levels were measured via TaqMan microRNA assays. Patients with CRC had significantly higher ex‑miR‑125b levels than healthy controls. In patients with partial responses, ex‑miR‑125b levels at the Response Evaluation Criteria in Solid Tumors (RECIST) judgment point were significantly lower than those measured before treatment. In patients with SD, ex‑miR‑125b levels did not differ before and during treatment. In patients with PD, ex‑miR‑125b levels at the RECIST judgment point were significantly higher than those measured before treatment. These changes in ex‑miR‑125b levels were significantly different between groups even 1 month after the initiation of chemotherapy. Progression‑free survival (PFS) was significantly worse in patients with high baseline ex‑miR‑125b levels than in those with low levels. In the Cox analysis, baseline ex‑miR‑125b levels and KRAS mutation were indicated to be independent prognostic factors for PFS. The present results suggest that plasma ex‑miR‑125b levels may be useful for the early detection of resistance to mFOLFOX6‑based first‑line chemotherapy. Furthermore, ex‑miR‑125b before chemotherapy is a predictive biomarker for PFS in patients with advanced/recurrent CRC.


  • Exosome‐encapsulated microRNA‐4525, microRNA‐451a and microRNA‐21 in portal vein blood is a high‐sensitive liquid biomarker for the selection of high‐risk pancreatic ductal adenocarcinoma patients

    by Sachiyo Kawamura, Hisae Iinuma, Keita Wada, Kunihiko Takahashi, Shunryo Minezaki, Masahiko Kainuma, Makoto Shibuya, Fumihiko Miura, Keiji Sano

    Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with poor prognosis. This is due to late diagnosis and lack of reliable prognostic biomarkers. In this study, we focused on exosomal microRNA (miRNA) in portal vein blood (PVB) as a potential biomarker to identify patients at high‐risk for recurrence and poor postoperative outcome.Methods: Exosomal miR‐4525, miR‐451a and miR‐21 expressions were assessed using PVB and peripheral blood (PB) collected from 55 PDAC patients during curative pancreatectomy. Correlation between the miRNA expressions and clinical outcomes, and target genes expressions was investigated.Results: Exosomal miR‐4525, miR‐451a and miR‐21 levels were upregulated in PVB, which were higher than those in the PB. High expression of miR‐4525, miR‐451a and miR‐21 in PVB was associated with recurrence with a higher sensitivity, specificity, and accuracy than that in PB. Cox regression analysis showed miR‐4525, miR‐451a and miR‐21 levels in PVB were independent prognostic factors for overall survival and disease‐free survival. There was a negative correlation between the expressions of miR‐4525 and MEN1 mRNA, miR‐451a and CAB39 mRNA, and t miR‐21 and PDCD4 mRNA.Conclusions: miR‐4525, miR‐451a and miR‐21 in PVB are potential biomarkers identifying patients at high‐risk for recurrence and poor survival in resected PDAC patients.


  • Exosome‑encapsulated microRNA‑23b as a minimally invasive liquid biomarker for the prediction of recurrence and prognosis of gastric cancer patients in each tumor stage

    by Yoshimasa Kumata, Hisae Iinuma, Yusuke Suzuki, Daisuke Tsukahara, Hironori Midorikawa, Yuichi Igarashi, Naruyoshi Soeda, Takashi Kiyokawa, Masahiro Horikawa, Ryoji Fukushima

    Recently, exosome‑encapsulated microRNAs (miRNAs) have been attracting attention as stable and minimally invasive biomarkers in cancer patients. The aim of the present study was to clarify the value of plasma exosomal microRNA‑23b (miR‑23b) as a diagnostic and prognostic biomarker in gastric cancer (GC) patients at each tumor stage. We first selected recurrence specific exosomal miRNA by miRNA microarray from 6 GC patients (stage I) with or without recurrence, and 3 healthy volunteers. In this analysis, miR‑23b demonstrated the most significant change. Subsequently, we validated the usefulness of miR‑23b as a biomarker using the plasma exosome samples collected from 232 GC patients and 20 healthy volunteers. miR‑23b levels were evaluated by Taqman microRNA assays. Exosomal miR‑23b levels of GC patients were significantly lower than those of the healthy controls. A significant association was revealed between the plasma exosomal miR‑23b levels and the expression of miR‑23b in primary tumor tissues. Concerning the pathological condition, miR‑23b demonstrated a significant association with tumor size, depth of invasion, liver metastasis and TNM stage. The overall survival (OS) rates of low‑miR‑23b patients were significantly worse than those of high‑miR‑23b patients at stage I, II, III and IV. The disease‑free survival (DFS) rates of low exosomal miR‑23b patients were significantly worse than those of high‑miR‑23b patients at stage I, II and III. Cox multivariate analysis indicated that exosomal miR‑23b was an independent prognostic factor for OS and DFS at each tumor stage. Our results revealed that exosomal miR‑23b has potential as minimally invasive predictive biomarker for the recurrence and prognosis of GC in patients at all stages.


  • Exosome‑encapsulated microRNA‑223‑3p as a minimally invasive biomarker for the early detection of invasive breast cancer

    by Mio Yoshikawa, Hisae Iinuma, Yasuko Umemoto, Takako Yanagisawa, Akiko Matsumoto, Hiromitsu Jinno

    Patients diagnosed preoperatively with ductal carcinoma in situ (DCIS) breast cancer have the potential to develop invasive ductal carcinoma (IDC). The present study investigated the usefulness of exosome‑encapsulated microRNA‑223‑3p (miR‑223‑3p) as a biomarker for detecting IDC in patients initially diagnosed with DCIS by biopsy. The potential association between miR‑223‑3p and clinicopathological characteristics was examined in patients with breast cancer. Exosomes of 185 patients with breast cancer were separated from plasma by ultracentrifugation. Initially a microRNA (miRNA) microarray was examined to reveal the invasion specific miRNAs using exosomes collected from 6 patients with breast cancer, including 3 DCIS patients, 3 IDC patients and 3 healthy controls. In the miR microarray analysis the miR‑223‑3p levels of IDC patients demonstrated the highest fold‑change compared with those in the DCIS patients and healthy controls. The potential of miR‑223‑3p for cell proliferation and cell invasion were examined in vitro using MCF7 cells transfected with the miR‑223‑3p gene. MCF7 cells transfected with the miR‑223‑3p gene significantly promoted cell proliferation and cell invasive ability (P<0.05). The plasma exosomal miR‑223‑3p levels of the other 179 patients with breast cancer and 20 healthy controls were measured using TaqMan miR assays. The exosomal miR‑223‑3p levels of the patients with breast cancer were significantly increased compared with the healthy controls (P<0.01). A statistically significant association was observed between the exosomal miR‑223‑3p levels and histological type, pT stage, pN stage, pathological stage, lymphatic invasion and nuclear grade (P<0.05). The exosomal miR‑223‑3p levels of IDC patients (stage I) and upstaged IDC patients (stage I) were significantly higher compared with the DCIS patients (P<0.05). These results suggest that exosomal miR‑223‑3p may be a useful preoperative biomarker to identify the invasive lesions of DCIS patients diagnosed by biopsy. In addition, plasma exosome‑encapsulated miR‑223‑3p level was significantly associated with the malignancy of breast cancer.


  • Usefulness of exosome‐encapsulated microRNA‐451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma

    by Kunihiko Takahasi, Hisae Iinuma, Keita Wada, Shunryo Minezaki, Sachiyo Kawamura, Masahiko Kainuma, Yutaka Ikeda, Makoto Shibuya, Fumihiko Miura, Keiji Sano

    Background: MicroRNAs (miRNAs) encapsulated in the exosomes of plasma is of interest as stable and minimally invasive biomarkers for recurrence and prognosis in cancer patients. The aim of this study was to clarify the predictive and prognostic value of plasma exosomal microRNA‐451a (miR‐451a) in patients with pancreatic ductal adenocarcinoma (PDAC).Methods: Microarray‐based expression profiling of miRNAs derived from exosomes in the plasma of six PDAC patients with UICC stage II was employed to identify a biomarker to distinguish between patients with and without recurrence. For validation analysis, plasma exosome samples of other 50 PDAC patients were measured by TaqMan MicroRNA assays.Results: In the miRNA microarray analyses, miR‐451a showed the highest upregulation in the stage II patients who showed recurrence after surgery. In the relationship to pathological factors, exosomal miR‐451a showed a significant association with tumor size and stage. The overall survival (OS) and disease‐free survival rates (DFS) of the high exosomal miR‐451a patients were significantly worse than those of the low miR‐451a patients. In Cox proportional hazards model analysis, exsomal miR‐451a showed significance to OS and DFS.Conclusions: Plasma exosomal miR‐451a levels may be a useful minimally invasive biomarker for the prediction of recurrence and prognosis in PDAC patients.


  • Open Access

    Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

    by Hitoshi Dejima, Hisae Iinuma, Rie Kanaoka, Noriyuki Matsutani, Masafumi Kawamura

    Predictive biomarkers for the recurrence of non‑small cell lung cancer (NSCLC) in patients who have received curative resection are important for cancer treatment. The functional microRNAs (miRNAs/miRs) in the exosomes of plasma and serum samples are of interest as stable and non‑invasive biomarkers for recurrence in cancer patients. The aim of the present study was to clarify the usefulness of plasma exosomal miRNAs as biomarkers for the prediction of recurrence in NSCLC following curative resection. First, microarray‑based expression profiling of miRNAs derived from exosomes in the plasma of 6 patients was employed to identify a biomarker that distinguishes between patients with and without NSCLC recurrence. In the miRNA microarray analyses, the exosomal miR‑21 and miR‑4257 levels of the NSCLC patients showed marked upregulation in those individuals with recurrence compared with those without recurrence and healthy individuals. These two miRNAs were thus selected as recurrence‑specific biomarkers and their potential was evaluated in a separate cohort of 195 NSCLC patients. In comparison to the levels in 30 healthy individuals, exosomal miR‑21 and miR‑4257 levels showed a significant increase in the NSCLC patients (P<0.01). When evaluating the clinicopathological significance of these miRNAs, exosomal miR‑21 showed a significant association with tumor size and tumor‑node‑metastasis (TNM) stage (P<0.05). Exosomal miR‑4257 showed a significant association with histological type, lymphatic invasion and TNM stage (P<0.05). The disease‑free survival (DFS) rates of high exosomal miR‑21 patients were significantly worse than those of low exosomal miR‑21 patients (P<0.05), and the DFS rates of patients with high exosomal miR‑4257 levels were significantly worse than those with low exosomal miR‑4257 levels (P<0.01). In the Cox multivariate analysis, plasma exosomal miR‑21 and miR‑4257 expression showed a significance association with DFS (P<0.05). These results suggest that plasma exosomal miR‑21 and mir‑4257 expression has potential as a predictive biomarker for recurrence in NSCLC patients who have received curative resection.


  • Open Access

    Alteration of tumor markers may predict survival in colorectal cancer patients treated with TAS-102 or regorafenib as salvage-line chemotherapy: a single-institutional experience

    by Keiji Matsuda, Keijiro Nozawa, Kohei Ohno, Yuka Okada, Takahiro Yagi, Mitsuo Tsukamoto, Yoshihisa Fukushima, Takuya Akahane, Atsushi Horiuchi, Ryu Shimada, et al.

    • 1 September 2016
      • Vol. 43  (9) , 1030-5

    [Anti-PD-1 Antibody Drugs - Potential of Plasma PD-L1 Protein as a Biomarker].

    by Hisae Iinuma, Noriyuki Matsutani, Hirofumi Uehara, Masafumi Kawamura

    The superior therapeutic effects of antibodies targeting immune checkpoints have been reported in the treatment of various cancers including non-small cell lung cancer(NSCLC)and malignant melanoma. However, the risk of reactivity against selfantigens and the high prices of these drugs are major concerns. Previously, PD-L1 protein expression and the number of infiltrating T cells in tumor tissues were investigated by immunohistochemical staining, as biomarkers for therapeutic anti-PD- 1 antibodies. However, further research into the clinical significance of PD-L1 expression in tumor tissues is still required. A promising and comprehensive gene mutation analysis of tumor tissues and T cell repertoire analysis has recently been undertaken. Liquid biopsy, which has the benefit of being minimally invasive, has also been investigated. We are currently, investigating the utility of plasma PD-L1 protein levels as a predictive biomarker of prognosis in NSCLC. Furthermore, it is important to explore useful biomarkers and develop reliable companion diagnostics for the individualized treatment with immune checkpoint drugs.